Prostate Cancer Death Linked With Shorter Sleep Duration

Video

This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.

In this video, Susan M. Gapstur, PhD, MPH, of the American Cancer Society in Atlanta, discusses an analysis of two large, long-term cohort studies-Cancer Prevention Study-I and Cancer Prevention Study-II-that found that sleep duration was linked with an increased risk of death among patients with prostate cancer.

Results of the study were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

The biological mechanism behind this association is unclear, but research has shown that lack of sleep and the presence of light at night can affect melatonin production, and that low melatonin production can lead to an increase in genetic mutations and can limit DNA repair.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content